Treats myasthenia gravis. ANDA 211181, held by Mlv. Pyridostigmine Bromide.
As of Nov 16, 2026, ANDA 211181 (Pyridostigmine Bromide), held by Mlv, was first approved by FDA on Jul 20, 2018, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Pyridostigmine bromide tablets are useful in the treatment of myasthenia gravis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 20, 2018 | Original application | Approved | None posted |
| Pyridostigmine Bromide60MG · tablet;oral | Pyridostigmine Bromide | Rx |
| Pyridostigmine Bromide30MG · tablet;oral | Pyridostigmine Bromide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters